Novartis Tightens Stance Over Gleevec In India
Novartis AG on Thursday strengthened its stance on patenting its cancer treatment Gleevec in India, arguing that a modification to a key section of the country's patent laws governing whether companies...To view the full article, register now.
Already a subscriber? Click here to view full article